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Coronavirus disease 2019 (COVID-19) is an acute respiratory 
tract infection that is caused by severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2). It presents with 
symptoms with severity ranging from a mild flu-like illness to 
severe viral pneumonia that is potentially fatal.[1,2] Symptoms 
may start from 2 days to 2 weeks following exposure to the 
virus, with some of the patients being asymptomatic.[3] Diabetes 
mellitus is characterized by high blood glucose concentration 
resulting from defects in insulin secretion, insulin action, 
or both.[4] The relationship between diabetes and infection 
has long been clinically recognized.[5] Nevertheless, the fact 
remains that controversies exist regarding whether diabetes 
mellitus itself indeed increases susceptibility and impacts 
outcomes from infections, including SARS-CoV-2, or the renal 
and cardiovascular comorbidities that are often associated with 
diabetes are the main factors involved.[6]
Despite the ample publications and reports on blood sugar control 
in different illnesses, a literature search on blood sugar patterns in 
COVID-19 patients with severe disease did not show any report. 
Scarce data exist on glucose metabolism and the development 
of acute complications of diabetes mellitus in patients with 
COVID-19. Hence, we reported a case of a 52-year-old Nigerian 
man known hypertensive heart disease patient with undiagnosed 
diabetes mellitus who presented with severe COVID-19 in heart 
failure and difficult to control blood sugar until the 10th day.
case RePoRt
A 52-year-old male  civil servant obese, known hypertensive 
heart disease patient who presented to our emergency triage 
unit with complaints of fever, cough, difficulty with breathing, 
Diabetes mellitus in coronavirus disease 2019 (COVID-19) patients is associated with poor outcomes due to poorly understood reasons inclusive 
of blood sugar patterns. Hence, we report a case of a 52-year-old Nigerian man known hypertensive heart disease patient, previously undiagnosed 
diabetes mellitus patient with difficulty in blood sugar control, heart failure, and persistent severe acute respiratory syndrome coronavirus 2 8 weeks 
after he tested positive. A 52-year-old male civil servant obese, known hypertensive heart disease patient presented with complaints of fever, cough, 
difficulty with breathing, headache, and generalized body weakness. At presentation, he had respiratory distress with low oxygen saturation of 78% and 
hyperglycemia (blood sugar of 40 mmol/l). His body mass index was 35.9 kg/m2. Chest radiography showed ground-glass appearance with cardiomegaly. 
Over the next 10 days on admission, his blood sugar fluctuated between hyperglycemia and an episode of hypoglycemia with occasional euglycemia and 
had glycated hemoglobin of 10.8%. The full blood count was normal, electrolyte, urea and creatinine showed mild elevation of the urea and creatinine, 
other parameters were normal, while the lipid profile showed hypercholesterolemia. He received multiple doses of insulin, anti-hypertensive, lopinavir/
ritonavir, methylprednisolone, and azithromycin. The patient was weaned off oxygen after 10 days and discharged home 15 days after admission. This 
case report highlighted the challenges that may face a patient with undiagnosed diabetes mellitus and COVID-19. It also brings forth the need to expand 
research options in COVID-19 and risk factors associated with the disease as the world strives to control the global pandemic.
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Figure 1: Chest radiograph of the patient (not pattern)
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headache, generalized body weakness, and malaise of 5 days 
duration. There was an associated history of orthopnea and 
paroxysmal nocturnal dyspnea. He was not a known diabetic. 
He did not smoke cigarettes but ingested alcohol (an average 
of 5 units in a day). For the hypertensive heart disease, he took 
oral amlodipine/valsartan 10/160 mg, spironolactone 25 mg, 
clopidogrel 75 mg, and frusemide 20 mg daily for the past 
10 years. Examination findings at admission showed a severely 
obese middle-age man with a body mass index of 35.9 kg/
m2 and a waist circumference of 110 cm. He was in obvious 
respiratory distress, febrile with a temperature of 37.9°C, not 
pale, mild dehydration, not cyanosed, and had bilateral pitting 
pedal edema. The blood pressure was 140/90 mmHg; pulse 
rate was 102 bpm, regular, and full volume, oxygen saturation 
was 78% in room air, had bibasal crepitations on both lungs. 
The other systemic examination findings were not remarkable. 
He tested positive for SARS-CoV-2 using reverse transcriptase 
polymerase chain reaction. The investigation results showed a 
normal full blood count [Table 1]; chest X-ray showed ground 
glass appearance with cardiomegaly [Figure 1]; the point of 
admission random blood glucose was 40 mmol/l (laboratory). 
The blood sugar pattern showed hyperglycemia in the first 2 days 
of admissions. From day 3 to 10, he had a fluctuating blood sugar 
of hyperglycemia with occasional hypoglycemia [Figure 2].
Urinalysis showed pH = 6.2, glucose (++), protein (+), 
nitrite (+), and glycated hemoglobin (HbA1c) of 10.8%. The 
lipid profile showed hypercholesterolemia [Table 1]. The 
electrolyte, urea, and creatinine showed mild elevation of urea 
and creatinine, with other parameters being normal [Table 1].
He was managed as a case of known hypertensive heart 
disease in heart failure with diabetes mellitus and COVID-19. 
The patient received intravenous amoxicillin-clavulanic 
acid, methylprednisolone, torsemide, subcutaneous (Sc) 
enoxaparin, oral azithromycin, zinc sulphate, Vitamin C, 
amlodipine/valsartan, and spironolactone. The symptoms of 
respiratory distress and heart failure improved over 48 h on 
admission and the oxygen at 8–10 L/min he received through 
nonrebreathing facemask was reduced to 4-5 L/min 5 days into 
admission. He received 10 IU of soluble insulin for the first 
24 h without achieving euglycemia. On the 2nd day, he was 
switched to insulin infusion at 60 IU in 500 ml of normal saline 
6 h with hourly blood sugar check [Figure 2]. The glycemic 
Table 1: Laboratory data of the patient
Test name Result Units Normal ranges
Full blood count
Packed cell volume 38 % 35-53
White blood cell count 8800 /mm3 4.0-10.0
Platelet count 203 ×109/L 100-350
Neutrophil 61 % 45-75
Lymphocyte 31 % 25-45
Monocyte 5 % 3-7
Basophils 0 % 0-1
Eosinophils 3 % 1-3
Electrolyte, urea, and creatinine
Creatinine 128 umol/l 62-115
Urea 8.8 mmol/l  2.5-7.1
Sodium 143 mmol/l 135-145
Potassium 4.2 mmol/l 3.5-5.5
Chloride 100 mmol/l 98-108
Bicarbonate 24 mmol/l 21-28
Lipid profile
Total cholesterol 203 mg/dl ≤200
Triglycerides 192 mg/dl <200
HDL cholesterol 98 mg/dl >60
LDL cholesterol 66.6 mg/dl <100
HDL: High-density lipoprotein, LDL: Low-density lipoprotein
Figure 2: (a and b) Blood sugar pattern
b
a
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control was still suboptimal on the 3rd day, with the insulin 
in the infusion increased to 80 IU with blood sugar check, 
as shown in Figure 2. On the 4th day, he was commenced on 
Sc isophane human insulin 20 IU 8 h with a 2 h infusion of 
normal saline + 40 IU of insulin and Sc Glargine 20 IU nocte 
with blood sugar check as shown in Figure 2. This regimen 
was maintained until the 6th day before the withdrawal of the 
infusion. Subsequently, vildagliptin/metformin 50/1000 mg 
twice daily was added, and Sc soluble insulin 20 IU, Sc 
Glargine 20 IU nocte was continued for the 7th, 8th, 9th, and 10
th 
days with blood sugar check as shown in Figure 2.
From the 11th day, he was commenced on Sc premixed 
Lispro 28 IU AM and 14 IU PM and vildagliptin/metformin 
50/1000 mg twice daily with blood sugar checks, as shown 
in Figure 2. The regimen was continued till discharge on 
the fifteenth day and when proper glycemic control was 
achieved, as shown in Figure 2. He was maintained on tablets 
vildagliptin/metformin twice daily. He was weaned off oxygen 
therapy after 10 days on admission and discharged home 
15 days after the admission on oral medications. On follow-up, 
he had euglycemia that ranged between 5.0 and 6.0 mmol/l.
dIscussIon
Our patient was previously not a known diabetic but severely 
obese with markedly elevated random blood glucose on 
admission. He also had two-pluses of glucose in urinalysis 
with elevated HbA1c. Besides, he also presented with features 
of heart failure. Hence, he was diagnosed as a case of known 
hypertensive heart disease in heart failure with diabetes 
mellitus and COVID-19. While the features of heart failure and 
respiratory distress improved following the commencement of 
treatments, he had persistent hyperglycemia, which extended 
to the 10th day on admission with some difficulty before we 
achieved control of his blood sugar. He also had nitrite in the 
urinalysis, which could be explained by the lowered immunity 
in the patient, most likely from dysglycemia as there were no 
urinary symptoms.
Infection with SARS-CoV-2 in those with diabetes mellitus 
possibly triggers higher levels of stress conditions, with the more 
significant release of hyperglycemic hormones, for example., 
glucocorticoids and catecholamines, leading to hyperglycemia, 
and abnormal glucose variability.[7,8] Hyperglycemia can cause 
injury to a large number of organs and tissues.[9] Most cells 
in humans adapt to the rate of intracellular glucose transport 
under hyperglycemic conditions. However, βeta cells are 
unable to adapt and rather equilibrate their intracellular glucose 
level to the extracellular concentrations. Hence, they are more 
susceptible to the effect of hyperglycemia.[10-12] Hyperglycemia 
can cause acute and chronic complications that represent 
important determinants of morbidity and mortality.[13]
Diabetes and uncontrolled glycemia are significant predictors 
of severity and deaths in patients infected with different 
viruses, including the 2009 pandemic influenza A (H1N1),[14] 
SARS-CoV,[15] and Middle East respiratory syndrome-CoV.[16] 
Besides, the corticosteroids administered to hospitalized patients 
may cause acute hyperglycemia, suboptimal glycemic control, 
more extended hospital stays, and increased morbidity and 
mortality.[17,18] In the current SARS-CoV-2 pandemic, some 
studies did not find a clear association between diabetes and 
severe disease.[19,20] A recent meta-analysis could not confirm 
that diabetes increased the risk of COVID-19 infection but did 
find that it worsened the outcome.[21]
Individuals with marked abdominal obesity also have 
mechanical respiratory issues, with reduced ventilation of the 
basal part of the lungs, increasing the risk of pneumonia and 
hypoxemia.[22] Independent of diabetes, obesity is a significant 
risk factor for morbidity and mortality in COVID-19 infection. 
In a study from Italy, 48% of patients with COVID-19 admitted 
to an intensive care unit were obese.[23]
There are concerns in patients of undiagnosed diabetes mellitus 
contracting COVID-19 infections as they have chances of a 
severe manifestation of pulmonary pathology. The unexplained 
interaction between diabetes mellitus and COVID-19 may set up 
a cascade of events in which COVID-19 produces critical poor 
glycemic control, which worsens the severity of COVID-19.[24] 
The cytokine storm in COVID-19 may induce some form 
of insulin resistance and directly cause pancreatic beta-cell 
destruction, and this may lead to worsening of glycemic control 
in patients of diabetes mellitus due to the massive release of 
cytokines and proinflammatory mediators.[24] Because of the 
increased mortality risk of diabetes mellitus with COVID-19, 
undiagnosed diabetes mellitus patients may be one of the worst 
sufferers if they happen to contract COVID-19 infection. The 
higher percentage of undiagnosed diabetes mellitus patients in 
Africa, in the scenario of the COVID-19 pandemic, may also 
progress to morbid states with COVID-19 and may add up to 
the mortality rates.
conclusIon
This case report highlighted the challenges that may face a 
patient with undiagnosed diabetes mellitus and COVID-19. 
It also brings forth the need to expand research options in 
COVID-19 and risk factors associated with the disease as the 
world strives to control the global pandemic.
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